secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGENUS INC (AGEN)
CIK:        0001098972
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001193125-25-273266
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agenus reports Q3 net income on MiNK gain; France reimburses BOT/BAL access
---------------------------------------------------------------------------

- France authorizes reimbursed compassionate access for BOT/BAL in refractory MSS mCRC; patients under treatment.
- BOT/BAL shows 42% two-year OS, 20.9-month median OS in 123 heavily pretreated MSS mCRC patients.
- Phase 3 BATTMAN trial initiated Q4 2025 across 100+ sites in Canada, France, Australia, NZ.
- MiNK deconsolidation generates ~$100.9M gain; net income for Q3 and nine-month periods.
- Zydus provides $10M bridge facility ahead of $91M closing; equity at $7.50/share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1098972/000119312525273266/0001193125-25-273266-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1098972/000119312525273266/agen-20251110.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-273266

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer